Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

The agreement will expand market access for Dyadic's recombinant protein products through IBT's established sales channels.

Mar. 16, 2026 at 11:20am

Got story updates? Submit your updates here. ›

Dyadic Applied BioSolutions, a global biotechnology company, has entered into an original equipment manufacturer (OEM) distribution agreement with Integrated Biotherapeutics, LLC, d/b/a IBT Bioservices, a life sciences reagent manufacturer and distributor. Through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT's established sales channels, expanding market access and supporting Dyadic's objective of generating ongoing, product-based revenues.

Why it matters

This partnership represents an important step in Dyadic's transition from R&D-driven revenue toward commercial product sales, enabling Dyadic-produced products to reach the market through established global distribution channels. Agreements like this are central to Dyadic's strategy as it focuses on direct sales, OEM relationships, and other commercialization pathways to drive growth and build durable revenue streams over time.

The details

The initial products expected to be offered under the agreement include recombinant DNase I and recombinant transferrin, with a focus on research-use-only (RUO) applications. Dyadic expects to offer both human and bovine transferrin, along with additional cell culture–relevant recombinant proteins, as part of a broader and expanding product portfolio. This relationship complements Dyadic's recent portfolio and manufacturing expansion initiatives and supports the Company's ability to commercialize a broader range of recombinant protein products across multiple end markets.

  • The agreement was announced on March 16, 2026.

The players

Dyadic Applied BioSolutions

A global biotechnology company that uses its proprietary microbial platforms to produce recombinant proteins that are sold or licensed to partners across the life sciences, food and nutrition, and bio-industrial markets.

IBT Bioservices

A premier provider of specialized life sciences reagents and preclinical contract research services supporting global research in infectious disease, biodefense, and immunology.

Joe Hazelton

President and Chief Operating Officer of Dyadic Applied BioSolutions.

Got photos? Submit your photos here. ›

What they’re saying

“This agreement is a meaningful milestone for Dyadic. It represents an important step in our transition from R&D-driven revenue toward commercial product sales, enabling Dyadic-produced products to reach the market through established global distribution channels. Agreements like this are central to our strategy as we focus on direct sales, OEM relationships, and other commercialization pathways to drive growth and build durable revenue streams over time.”

— Joe Hazelton, President and Chief Operating Officer of Dyadic Applied BioSolutions

What’s next

The collaboration provides flexibility for potential future expansion, which could include Dyadic supplying market-ready products for distribution or licensing production strains to support partner-led manufacturing, consistent with Dyadic's multi-channel commercialization approach.

The takeaway

This partnership with IBT Bioservices represents a significant milestone for Dyadic, as it transitions from an R&D-focused company to one that can commercialize its recombinant protein products through established global distribution channels, supporting the company's long-term objective of building durable revenue streams.